Proteins and Peptides

08 Jan 2008 Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
08 Jan 2008 Chemokine Therapeutics Receives Approval From FDA to Commence Phase II Study
07 Jan 2008 Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
07 Jan 2008 Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
07 Jan 2008 Catalyst Biosciences and Centocor Research & Development, inc. fForm collaboration to discover and develop engineered protease therapeutics
07 Jan 2008 Baxter Announces Recombinant Factor IX Development Program for Hemophilia B
03 Jan 2008 Protox announces positive final results from BPH study
21 Dec 2007 Lundbeck expands agreement with PAION for desmoteplase
21 Dec 2007 Pfizer Receives Approvable Letter from FDA for Dalbavancin
21 Dec 2007 Pharming Submits Request For Re-examination Of CHMP Opinion For European Marketing Authorization Application For Rhucin(R)
21 Dec 2007 Jerini Receives NDA Filing Acceptance and Priority Review from the FDA for Icatibant in the Treatment of HAE
21 Dec 2007 ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
20 Dec 2007 Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
20 Dec 2007 Altor BioScience Advances Clinical Trial for Targeted Cancer Therapeutic, ALT-801
19 Dec 2007 BioLineRx Announces Presentation of Pre-Clinical Data Demonstrating that BL-2030 Reduces Tumor Growth and Prevents Metastasis in Model of Prostate Cancer
19 Dec 2007 Altus Pharmaceuticals Reacquires ALTU-238 Global Development and Commercialzation Rights
18 Dec 2007 ZymoGenetics Begins Phase 2 Clinical Trial of IL-21 in Melanoma
18 Dec 2007 Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
17 Dec 2007 Novo Nordisk licenses global rights to potential new haemostasis therapy
14 Dec 2007 Shire expands its gastrointestinal portfolio through in-licensing Celiac disease Phase 2 product from Alba Therapeutics Corporation
13 Dec 2007 Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies
13 Dec 2007 Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
12 Dec 2007 Final phase 3 study confirms very favourable effect of liraglutide on blood glucose control and body weight
11 Dec 2007 ZymoGenetics Presents PEG-Interferon Lambda Phase 1a Data
11 Dec 2007 Medicis and Revance Announce Strategic Collaboration

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top